(Q43024877)

12 November 2017

title

Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus (English)

1 reference

12 November 2017

7

Tsutomu Chiba

1 reference

12 November 2017

Shuji Yamamoto

1

1 reference

12 November 2017

Hiroshi Nakase

2

1 reference

12 November 2017

Minoru Matsuura

3

1 reference

12 November 2017

Yusuke Honzawa

4

1 reference

12 November 2017

Satohiro Masuda

5

1 reference

12 November 2017

Ken-ichi Inui

6

1 reference

12 November 2017

publication date

1 May 2010

1 reference

Journal of Gastroenterology and Hepatology

12 November 2017

published in

1 reference

12 November 2017

volume

25

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

886-891

1 reference

Inflammatory Bowel Disease

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Inflammatory bowel disease: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Predictors of early response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Clinical pharmacokinetics of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2009.06206.X

10.1111/J.1440-1746.2009.06206.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference